Page 9 - Informa Pharma Intelligence News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Minimizing Luck In Study Feasibility Part 1: Best Practices By Ashley Schwalje, Senior GTM Manager, Clinical R&D Strategy, Informa Pharma Intelligence and Daniel Chancellor, Thought Leadership Director, Informa Pharma Intelligence Two thirds of clinical trial sites are unable to meet original enrollment goals, with half of sites recruiting either a single patient or failing completely. Study sponsors must therefore scrutinize their current approaches to feasibility, as recruitment is such a critical part of overall trial success. This article, the first of a two-part series, summarizes the cu...

View Comments When Johnson & Johnson's COVID-19 vaccine was authorized for use in late February, public health officials emphasized that it was just as good as the others. It was less effective, but because it requires only a single shot for full protection and is easier to distribute, it was a top choice for many people. Since then, the J&J vaccine has been given far less often than the other two authorized vaccines, accounting for one-tenth as many shots as Moderna's vaccine, which is given less often than Pfizer-BioNTech's. Recently, three pieces of information have come to light making...

Understanding of Clinical Trials Up Among Americans Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligence’s 2020 Pulse Report when the COVID-19 vaccines had yet to be made available in the United States. 1 In fact, the percentage of Americans saying they’d be more likely to take a COVID-19 vaccine if they had more information on the clinical trials has dropped by half since 2020 (14% from 28%). Furthermore, the number of Americans saying they’d be more likely to participate in a clinical tri...

Understanding of Clinical Trials Up Among Americans Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligence’s 2020 Pulse Report when the COVID-19 vaccines had yet to be made available in the United States. 1 In fact, the percentage of Americans saying they’d be more likely to take a COVID-19 vaccine if they had more information on the clinical trials has dropped by half since 2020 (14% from 28%). Furthermore, the number of Americans saying they’d be more likely to participate in a clinical tri...

Informa Business Intelligence: While Over Three-Quarters of Americans Are Willing to Take at Least One of the Authorized COVID-19 Vaccines, Nearly a Quarter Are Still Hesitant as the U.S. Changes Course on Mitigation Strategy Understanding of Clinical Trials Up Among Americans Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligence's 2020 Pulse Reportwhen the COVID-19 vaccines had yet to be made available in the United States. 1 In fact, the percentage of Americans saying they'd be more likely to ta...